Summary & Overview

Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures without MCC: Inpatient Reimbursement Overview

DRG 279 encompasses catheter-directed and ultrasound accelerated thrombolysis of peripheral vascular structures without a Major Complication or Comorbidity, covering targeted clot-dissolving procedures in arteries and veins. It matters for inpatient reimbursement because procedural resources, device utilization, and hospital stay in this Diagnosis-Related Group drive the Centers for Medicare & Medicaid Services payment for the admission.

Ultrasound Accelerated ThrombolysisDRG Ultrasound Accelerated and Other Thrombolysis of Peripheral Vascular Structures without MCCDRG 279Diagnosis-Related GroupInpatient ReimbursementMedicareVascular SurgeryInterventional RadiologyThrombolysisCatheter-Directed Therapy

DRG 279 Overview

DRG 279 covers hospital admissions for ultrasound accelerated and other catheter-directed thrombolysis procedures of peripheral vascular structures when no Major Complication or Comorbidity is present. It applies to patients undergoing targeted dissolution of thrombus in peripheral arteries or veins using infusion catheters and adjunctive ultrasound or mechanical assistance. This Diagnosis-Related Group is important for Medicare payment because it groups procedural intensity, device use, and length of stay to determine the inpatient reimbursement rate. Hospitals use this classification to align coding and billing with the Centers for Medicare & Medicaid Services payment methodology.

Clinical Trials

Acute procedural efficacy and safety studies assessing ultrasound-accelerated thrombolysis versus standard catheter-directed thrombolysis for acute peripheral arterial or venous thromboembolic events. These trials enroll inpatient adults presenting with limb-threatening or symptomatic peripheral arterial occlusions or extensive deep vein thrombosis shortly after symptom onset, measuring time to reperfusion, limb salvage rates, bleeding complications, and in-hospital resource utilization. Results inform procedural selection during the index hospitalization and affect payer decisions about coverage of advanced thrombolytic delivery techniques and expected lengths of stay.
Comparative effectiveness and cost-effectiveness studies evaluating endovascular thrombolysis combined with adjunctive mechanical thrombectomy or angioplasty versus endovascular thrombolysis alone in subacute peripheral vascular occlusions. These studies target patients who may have failed initial anticoagulation or present with subacute ischemia, assessing long-term patency, need for reintervention, functional limb outcomes, and total cost across the episode of care. Findings guide clinicians on optimal procedural bundles and help hospitals and payers predict downstream costs and readmission risk associated with different interventional strategies.
Post-discharge outcomes and rehabilitation research monitoring readmission, limb function, chronic pain, venous insufficiency, and quality-of-life after inpatient ultrasound-accelerated or other thrombolysis procedures. Cohorts include survivors of inpatient thrombolytic interventions followed for months to years to quantify late complications, anticoagulation management patterns, and utilization of outpatient services or secondary procedures. This evidence is relevant for care coordination, discharge planning, and payer evaluations of long-term value and coverage of post-acute services.

Related Codes

305-HYPERTENSION-WITHOUT-MCC

Hypertension without MCC: Inpatient Reimbursement Overview

240-AMPUTATION-FOR-CIRCULATORY-SYSTEM-DISORDERS-EXCEPT-UPPER-LIMB-AND-TOE-WITH-CC

Amputation for Circulatory System Disorders Except Upper Limb and Toe with CC: Inpatient Reimbursement Overview

270-OTHER-MAJOR-CARDIOVASCULAR-PROCEDURES-WITH-MCC

Other Major Cardiovascular Procedures with MCC: Inpatient Reimbursement Overview

271-OTHER-MAJOR-CARDIOVASCULAR-PROCEDURES-WITH-CC

Other Major Cardiovascular Procedures with CC: Inpatient Reimbursement Overview

286-CIRCULATORY-DISORDERS-EXCEPT-AMI-WITH-CARDIAC-CATHETERIZATION-WITH-MCC

Circulatory Disorders Except AMI with Cardiac Catheterization with MCC: Inpatient Reimbursement Overview

304-HYPERTENSION-WITH-MCC

Hypertension with Major Complication or Comorbidity: Inpatient Reimbursement Overview

253-OTHER-VASCULAR-PROCEDURES-WITH-CC

Other Vascular Procedures with CC: Inpatient Reimbursement Overview

321-PERCUTANEOUS-CARDIOVASCULAR-PROCEDURES-WITH-INTRALUMINAL-DEVICE-WITH-MCC-OR-4-ARTERIES-INTRALUMINAL-DEVICES

Percutaneous Cardiovascular Procedures with Intraluminal Device with MCC or 4+ Arteries/Intraluminal Devices: Inpatient Reimbursement Overview

252-OTHER-VASCULAR-PROCEDURES-WITH-MCC

Other Vascular Procedures with MCC: Inpatient Reimbursement Overview

273-PERCUTANEOUS-AND-OTHER-INTRACARDIAC-PROCEDURES-WITH-MCC

Percutaneous and Other Intracardiac Procedures with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 100

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.